| Bioactivity | S-2720 is a potent inhibitor of both human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) activity and HIV-1 replication. The binding sites of S-2720 and the nonnucleoside compounds overlap. The small pocket in the p66 subunit-BI-RG-587 (HY-10570) complex is most likely also the target of S-2720. S-2720 is a quinoxaline derivative, which is promising for research of HIV-1 infection[1]. |
| CAS | 146739-86-8 |
| Formula | C14H15ClN2O2S |
| Molar Mass | 310.80 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kleim JP, et al. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother. 1993 Aug;37(8):1659-64. |
S-2720
CAS: 146739-86-8 F: C14H15ClN2O2S W: 310.80
S-2720 is a potent inhibitor of both human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) activity and H
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.